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Dear Editor,
We have read with great interest the article by Foolad et al. reporting on the use of oral versus inhaled ribavirin (RBV) for the treatment of respiratory syncytial virus (RSV) infection in hematopoietic cell transplant (HCT) recipients in their center. 1 They conclude that oral RBV may be an effective alternative for aerosolized RBV.
While these results are surely promising in light of significant cost savings and availability of treatment, a few questions remain to be elucidated. As the authors stated, neither the optimal dosing regimen nor the optimal treatment duration of RBV are established yet. We recently hemoglobin may start to fall with plasma concentration >3.5 mg/L. 4, 5 Proposed oral treatment regimens found by our model comprising loading doses of either 11 mg/kg q8hrs for the first 24hrs or 8mg/kg q6hrs for the first 48hrs, followed by a maintenance dose of 4 mg/kg q12hrs or 8 mg/kg q24hrs may quickly attain target concentrations while preventing an overshoot in the RBV concentration and therefore a lower likelihood for developing anemia. 
